Eiger Capital is an active boutique Australian equities investment manager specialising in small companies. Eiger was founded in 2019 by Stephen Wood, Victor Gomes and David Haddad who have worked together since 2011. Prior to Eiger they were at a large asset management company also managing Australian small company funds. The team employs a high conviction, style-neutral approach to investing. The team is managing approximately $875 million as at 31 March 2025.
Our underlying investment philosophy is based on price to intrinsic value. More >>
Meet the Eiger investment team, who have over 95 years combined investment experience. More >>
The Eiger Australian Small Companies Fund offers an actively managed portfolio of small companies. More >>
View the latest performance of the Fund plus historical track record of the strategy. More >>
Our latest insights on small cap stocks, investment markets and press coverage.
Our latest analysis reveals that while overall market volatility has returned to pre-COVID levels, intra-month price swings are still high. Markets may seem calmer on the surface, but there’s plenty going on underneath.
Catch up on the latest market insights with these short Ausbiz TV interviews with Stephen Wood.
As we swing into the holiday season and the parcels from Black Friday continue to land on your doorsteps, it felt apt to unzip the “Buy Now, Pay Later” (BNPL) industry in more detail; particularly focusing on Zip. BNPL has transformed from a nascent industry into a mature, fully-fledged component of retail payments.
AI has certainly created a buzz over the past couple of years. While a lot of attention has been focussed on Nvidia, the global poster child for the AI sector, there has been a raft of cascading effects that have trickled down to related industries. An obvious one is data centres.
Although theranostics is a made-up fusion of two words, therapeutics and diagnostics, it has become an accepted new word, or neologism, to describe this rapidly emerging field of medical science. It seeks to be both a therapy and a diagnostic for cancer treatment.
